
Iconovo Q2 - An undramatic report with early signs of cost reductions

Redeye provides an update following Iconovo's Q2 report. The report was relatively undramatic, with quarterly figures broadly in line with our projections. However, we are encouraged by the early signs of cost reductions, which reflect the company's recent restructuring efforts. Following the report, we have made minor adjustments to our estimates, leading to a slightly revised base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Iconovo Q2 - An undramatic report with early signs of cost reductions